<DOC>
	<DOCNO>NCT01690689</DOCNO>
	<brief_summary>The purpose ass safety profile performance femoral resurface implant localized chondral lesion .</brief_summary>
	<brief_title>Investigation Customized Femoral Resurfacing Implant</brief_title>
	<detailed_description>The implant 's safety profile assess incidence subject seven identify implant-related clinical undesirable side effect . This analyzed one-side exact binomial test significance level 0.05 , 24 month post-operatively .</detailed_description>
	<mesh_term>Cartilage Diseases</mesh_term>
	<criteria>1 . Male female 2 . Age 30 ≤ 65 year 3 . Chondral defect femoral cartilage ICRS grade 3 ( severely abnormal cartilage defect &gt; 50 % cartilage depth ) grade 4 ( severely abnormal , cartilage depth ) medial lateral femoral condyle 4 . Cartilage lesion area &lt; 3.2 cm2 ( diameter &lt; 2 cm ) 5 . Failed earlier conservative surgical intervention lavage , abrasion , drill microfracture 6 . VASpain symptom &gt; 40 6 month 7 . The arthroscopic find corresponds expect ; size cartilage lesion correct significant pathology ( see CIP , `` Intraoperative checklist '' , Appendix I ) 8 . Capable completing selfadministered questionnaire 9 . Willing comply followup requirement study 10 . Signed informed consent 1 . BMI ≥ 35 kg/m2 ( severe obesity ) 2 . Instability deficiency soft tissue , vascular muscular insufficiency 3 . Metabolic disorder may impair bone formation 4 . Diabetes mellitus 5 . Smokers 6 . Diagnosis concomitant knee injury Investigator appreciate may interfere study participation ( i.e . may confound efficacy assessment heal involved knee joint level ) 7 . Irresolvable joint pain lossoffunction undeterminable cause 8 . Diagnosis concomitant meniscal injury involve knee require surgical intervention 9 . Loss joint space stand radiograph ( ≥ 1 Ahlbäckscale ( 05 ) ) 10 . Avascular necrosis 11 . Infections , systemic local 12 . Known metal allergy 13 . History inflammatory arthritis 14 . Pregnancy 15 . Pacemaker implant 16 . History drug substance abuse 17 . Systemic administration within 30 day prior study type corticosteroid , antineoplastic , immune stimulate immunosuppressive agent 18 . Participation another clinical trial use investigational new drug device within 30 day entrance study . 19 . Condition may impact outcome investigation judge Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>